Navigation Links
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Date:5/22/2008

the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
2. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... Calif. , July 30, 2015  Cleave ... and Trademark Office has granted the company a ... covering Cleave,s lead molecule CB-5083. This ... as inhibitors of p97," U.S. 9,062,026, allows for ... a first-in-class, highly selective oral inhibitor of p97, ...
(Date:7/30/2015)... Flexpoint Ford, a private equity firm focused ... that it has entered into a partnership with ... form Kastle Therapeutics, LLC (Kastle).  The new company, headquartered ... acquiring, developing and commercializing pharmaceuticals targeted toward diseases with ... therapies already approved for marketing, as well as clinical ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... DIEGO, Feb. 6, 2012   Neurelis, Inc. today announced ... (FDA) has cleared an Investigational New Drug application ... of NRL-1 for the treatment of acute breakthrough ... late 2011, Neurelis filed the IND based upon ...
... Association (PCMA) launched a new ad campaign in Oregon ... (PBMs).  The ad campaign – "That,s What PBMs ... , PBMs lower costs for employers, unions, and consumers ... , PBMs help patients make informed prescription drug decisions ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2PCMA Launches New Oregon Ad Campaign: 'That's What PBMs Do' 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels ... Waycross, Georgia. Start time will be 7:30 AM. The duathlon is a 2 mile run, ... swim in Laura Walker Lake, a 13 mile bike, and a 3 mile run. ...
(Date:7/31/2015)... ... July 31, 2015 , ... With the recent buzz ... individuals who remain undiagnosed, treatment options for patients are becoming more prevalent than ... therapy due to its overall lack of comfort and highly invasive nature, oral ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... OSF Healthcare ... results from the 2015 Most Wired Survey conducted by Hospitals & Health Networks. This ... system owned and operated by The Sisters of the Third Order of St. ...
(Date:7/30/2015)... ... 2015 , ... In a meaningful ritual intended to symbolize a final farewell ... have created an addiction graveyard. Sharing this with the public comes at a unique ... Hudson . Hudson (1945-2015) fell in love with the desert when he moved from ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... , , WASHINGTON, July 31 ... for Tobacco-Free Kids: , , (Logo: ... D.C. Council has taken an important step to protect the District,s kids ... cigarette tax by 50 cents to $2.50 per pack - the seventh ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , , Campaign ... After 4 months of college students and others wrestling with ... picked two winners for its nationwide sign design contest. The victors ... who is entering law school this fall at the University of ...
... , ALBANY, N.Y., July 31 ... New York throughout the week of August 3 - 7 ... New Yorkers access information on programs that provide prescription medicines for ... 8.2 percent, compared to 5.2 percent a year ago, the ...
... , , Partnership for ... WASHINGTON, July 31 The House Energy and Commerce ... legislation that would prohibit cost-sharing to Medicaid patients for recommended ... was supported by Partnership for Prevention, the American College of ...
... WASHINGTON, July 31 Last night, U.S. Rep. Lois Capps ... H.R. 3200, that would specifically include abortion in the health care ... Council Action President Tony Perkins had this to say on the ... up: , , "It has been clear ...
Cached Medicine News:Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 3Health News:House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: